AIMS: Pineal parenchymal tumours (PPTs) are rare neoplasms that are divided into pineocytoma (PC), pineoblastoma (PB) and PPT of intermediate differentiation (PPTID). Factors affecting the survival of patients with PPTs are morphological subtype and histological grading according to mitotic index and neurofilament immunostaining. Grading criteria to distinguish PPTIDs are difficult to define, particularly when using small specimens. The Ki67 labelling index (LI) might be helpful in distinguishing between grade II and III PPTIDs. Our study was performed to assess the predictive value of the Ki67 LI in a large cooperative series of PPTs and to evaluate whether inclusion of this data would improve and refine the World Health Organization classification. METHODS: A retrospective analysis of 33 PPTs was performed. The histological features of the tumours were reviewed and Ki67 LI scoring was evaluated by immunohistochemistry. Data were correlated with the patients' survival. RESULTS: The mean Ki67 LI was significantly different for tumour grades (0 in PC, 5.2 ± 0.4 in PPTID grade II, 11.2 ± 2.0 in PPTID grade III, 36.4 ± 6.2 in PB; P < 0.0001). However, there was no statistically significant difference in either overall or disease-free survival evaluated by the Kaplan-Meier method for patients with different grade tumours or Ki67 LI, possibly due to the different clinical management of patients in different centres. CONCLUSIONS: The Ki67 LI may be a useful additional tool for grading PPTs, more particularly in small tumour samples.
AIMS: Pineal parenchymal tumours (PPTs) are rare neoplasms that are divided into pineocytoma (PC), pineoblastoma (PB) and PPT of intermediate differentiation (PPTID). Factors affecting the survival of patients with PPTs are morphological subtype and histological grading according to mitotic index and neurofilament immunostaining. Grading criteria to distinguish PPTIDs are difficult to define, particularly when using small specimens. The Ki67 labelling index (LI) might be helpful in distinguishing between grade II and III PPTIDs. Our study was performed to assess the predictive value of the Ki67 LI in a large cooperative series of PPTs and to evaluate whether inclusion of this data would improve and refine the World Health Organization classification. METHODS: A retrospective analysis of 33 PPTs was performed. The histological features of the tumours were reviewed and Ki67 LI scoring was evaluated by immunohistochemistry. Data were correlated with the patients' survival. RESULTS: The mean Ki67 LI was significantly different for tumour grades (0 in PC, 5.2 ± 0.4 in PPTID grade II, 11.2 ± 2.0 in PPTID grade III, 36.4 ± 6.2 in PB; P < 0.0001). However, there was no statistically significant difference in either overall or disease-free survival evaluated by the Kaplan-Meier method for patients with different grade tumours or Ki67 LI, possibly due to the different clinical management of patients in different centres. CONCLUSIONS: The Ki67 LI may be a useful additional tool for grading PPTs, more particularly in small tumour samples.
Authors: Bryan K Li; Alexandre Vasiljevic; Christelle Dufour; Fupan Yao; Ben L B Ho; Mei Lu; Eugene I Hwang; Sridharan Gururangan; Jordan R Hansford; Maryam Fouladi; Sumihito Nobusawa; Annie Laquerriere; Marie-Bernadette Delisle; Jason Fangusaro; Fabien Forest; Helen Toledano; Palma Solano-Paez; Sarah Leary; Diane Birks; Lindsey M Hoffman; Alexandru Szathmari; Cécile Faure-Conter; Xing Fan; Daniel Catchpoole; Li Zhou; Kris Ann P Schultz; Koichi Ichimura; Guillaume Gauchotte; Nada Jabado; Chris Jones; Delphine Loussouarn; Karima Mokhtari; Audrey Rousseau; David S Ziegler; Shinya Tanaka; Scott L Pomeroy; Amar Gajjar; Vijay Ramaswamy; Cynthia Hawkins; Richard G Grundy; D Ashley Hill; Eric Bouffet; Annie Huang; Anne Jouvet Journal: Acta Neuropathol Date: 2019-12-09 Impact factor: 17.088
Authors: Michael A Paltsev; Victoria O Polyakova; Igor M Kvetnoy; George Anderson; Tatiana V Kvetnaia; Natalia S Linkova; Ekaterina M Paltseva; Rosa Rubino; Salvatore De Cosmo; Angelo De Cata; Gianluigi Mazzoccoli Journal: Oncotarget Date: 2016-03-15
Authors: Deena M A Gendoo; Ronak Ghanbari-Azarnier; Philip E D Chung; Jeff C Liu; Zhe Jiang; Jennifer Tsui; Dong-Yu Wang; Xiao Xiao; Bryan Li; Adrian Dubuc; David Shih; Marc Remke; Ben Ho; Livia Garzia; Yaacov Ben-David; Seok-Gu Kang; Sidney Croul; Benjamin Haibe-Kains; Annie Huang; Michael D Taylor; Eldad Zacksenhaus Journal: Nat Commun Date: 2020-04-14 Impact factor: 14.919